Products

What will AGI do for Anazocine?

This classification denotes an opioid receptor agonist with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2S5VMM2SG, chemically known as 4-beta-methoxy-1-methyl-4-alpha-phenyl-3-alpha,5-alpha-propanopiperidine but generally known as anazocine, which bears US NIH Compound Identifier 27213. European Medicines Agency schedules Anazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05504MIG. The term ANAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). ANAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anazocine under HS 29333999 and SITC 51574. As of Q4 2014, ANAZOCINE remains the US FDA Preferred Term for this commodity. Anazocine bears US NLM identifiers UMLS ID C2698110 and NCI Concept Code C77276. SMILES: O(C1(C2CCCC1CN(C2)C)C1CCCCC1)C.

How AGI delivers it

Four ways AGI delivers for Anazocine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Anazocine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Anazocine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Anazocine connects

measured by

  • Active Ingredient Potencymodel
  • Chiral Enantiomeric Excessmodel
  • Compound Puritymodel
  • Residual Solventmodel